|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:tacrolimus
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AD02
|
|
gptkbp:bioavailability
|
~50%
|
|
gptkbp:brand
|
gptkb:Envarsus_XR
|
|
gptkbp:contraindication
|
hypersensitivity to tacrolimus
|
|
gptkbp:drugClass
|
immunosuppressant
|
|
gptkbp:eliminatedIn
|
biliary
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:genericName
|
gptkb:tacrolimus_extended-release
|
|
gptkbp:halfLife
|
~31 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Envarsus XR
|
|
gptkbp:indication
|
prophylaxis of organ rejection in kidney transplant patients
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Veloxis_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP3A5)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adult kidney transplant recipients
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
headache
hypertension
tremor
nephrotoxicity
hyperkalemia
|
|
gptkbp:bfsParent
|
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:bfsLayer
|
6
|